The estimated Net Worth of James M Mock is at least $6.31 Million dollars as of 28 August 2024. Mr Mock owns over 329 units of Revvity stock worth over $1,029,424 and over the last 7 years he sold PKI stock worth over $2,554,654. In addition, he makes $2,723,038 as Sr. VP & CFO at Revvity.
Mr has made over 13 trades of the Revvity stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 329 units of PKI stock worth $37,930 on 28 August 2024.
The largest trade he's ever made was selling 6,080 units of Revvity stock on 20 September 2021 worth over $1,124,010. On average, Mr trades about 1,266 units every 53 days since 2018. As of 28 August 2024 he still owns at least 8,929 units of Revvity stock.
You can see the complete history of Mr Mock stock trades at the bottom of the page.
James M. Mock is the Sr. VP & CFO at Revvity.
As the Sr. VP & CFO of Revvity, the total compensation of Mr Mock at Revvity is $2,723,038. There are 3 executives at Revvity getting paid more, with Dr. Prahlad R. Singh Ph.D. having the highest compensation of $4,862,149.
Mr Mock is 44, he's been the Sr. VP & CFO of Revvity since . There are 18 older and 3 younger executives at Revvity. The oldest executive at Revvity Inc. is Peter Barrett, 67, who is the Independent Director.
James's mailing address filed with the SEC is 940, Winter Street, Prospectville, Waltham, Middlesex County, Massachusetts, 02451, United States.
Over the last 26 years, insiders at Revvity have traded over $204,298,889 worth of Revvity stock and bought 55,200 units worth $1,110,570 . The most active insiders traders include Alexis P Michas, Gregory L Summe, and Robert F Friel. On average, Revvity executives and independent directors trade stock every 25 days with the average trade being worth of $6,184,617. The most recent stock trade was executed by Andrew Okun on 13 April 2023, trading 2,435 units of PKI stock currently worth $332,402.
PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, the company delivers unique solutions to serve the diagnostics, life sciences, food, and applied markets. IT strategically partners with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Its dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index.
Revvity executives and other stock owners filed with the SEC include: